Everbright
VC Fund
Wan Chai, Hong Kong
Everbright is a VC fund in Wan Chai focused on Health Care and Biotechnology. Everbright is China’s cross-border investment and asset management company.
- Total investments:
- 55
- Last investment:
- Lead investor:
- 20%
- Fund size:
- $539M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Everbright invests in
Stages Everbright invests in
Countries Everbright invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 8 contacts → | |||
Investment Focus
Industry
- Health Care 10 (18%)
- Biotechnology 9 (16%)
- Manufacturing 9 (16%)
- Medical 6 (11%)
- Software 5 (9%)
Stage
- Series A 19 (35%)
- Series C 8 (15%)
- Series B 7 (13%)
- Series D 5 (9%)
- Angel 4 (7%)
Country
- China 37 (67%)
- United States 5 (9%)
- Iceland 1 (2%)
- Hong Kong 1 (2%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Chen Shuang
Executive Director and CEO
|
Executive Director and CEO | Total investments: 0 | Find email | |
Jiang Yuanzhi
Executive Director and Chief Investment Officer
|
Executive Director and Chief Investment Officer | Total investments: 0 | Find email | |
Tang Chi Chung Richard
Executive Director and CFO
|
Executive Director and CFO | Total investments: 0 | Find email | |
Tsang Frederick Sui Cheong
Chief Risk Officer
|
Chief Risk Officer | Total investments: 0 | Find email | |
Wong Tung Hung
Chief Administration Officer
|
Chief Administration Officer | Total investments: 0 | Find email | |
| See all 8 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Ractigen is an early-stage pharmaceutical company committed to bringing to market first-in-class therapies designed to selectively restore the expression of therapeutic genes silenced in diseased cells. Its core technology is based on a paradigm-shifting discovery made at the University of California San Francisco (UCSF) known as RNA activation(RNAa). Founded in 2016 by the pioneers in the field, Ractigen is developing a rich pipeline of candidate medicines for patients with unmet need. | $31M / Venture - Series Unknown / Jul 29, 2026 | ||
Topband Huachuang
|
Topband is a membrane material technology developer, mainly engaged in the research and development of special separation membrane materials. Its products are widely used in new energy, semiconductor, coal chemical and other fields. | $14.7M / Series C / May 26, 2026 | |
| YoungEn Technology is an automation equipment company that specializes in providing automated, intelligent production equipment solutions. | Series B / Jan 07, 2026 | ||
| KYinno is a drug development company that is dedicated to oncology drug development with a focus on immune treatments against cancer. | $35.5M / Series B / Dec 15, 2025 | ||
Xinyi Electronic Technology
|
Xinyi Electronics is an artificial intelligence application software developer, focusing on 5G communication technology services, artificial intelligence application software development, integrated circuits, semiconductor device special equipment, integrated circuit chips and products. | Series A / Jul 17, 2025 | |
| Terminus Group is an international leading Al smart service provider, shaping the next generation of technology with Artificial Intelligence & Internet of Things (AloT). They are mission driven, and are devoted to providing our customers with high quality products, which focused on AI cities, sustainable development, and robotics. They aim touse their AloT engine to integrate standalone products into smart solutions, eventually paving the way to a world of interconnected AI cities. | $276.6M / Series D / Apr 09, 2024 | ||
| Reforgene Medicine is a biomedical company that uses gene editing and genomic technology to develop new drugs intended to cure genetic diseases. | $15M / Series B / Apr 28, 2023 | ||
|
Grit Science
|
Grit Science is a gene therapeutics firm, that engages in the R&D of liver genes. | $15M / Series A / Mar 02, 2022 | |
| Innogen Pharmaceutical Technology is a high-tech, innovation-driven international pharmaceutical manufacturing, and R&D company. | $120M / Series A / Dec 23, 2021 | ||
Yinuo Pharmaceutical
|
Yinuo Pharmaceuticals is a small molecule inhibitor drug developer. | $120M / Series A / Dec 23, 2021 | |
| See all 55 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Everbright invest in?
Everbright invests primarily in Health Care, Biotechnology and Manufacturing startups, most often at Series A and Series C stage. Most of the 55 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Everbright?
Public channels for Everbright include LinkedIn, the website linked on this profile and Facebook. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Everbright?
The team at Everbright includes Chen Shuang (Executive Director and CEO), Jiang Yuanzhi (Executive Director and Chief Investment Officer) and Tang Chi Chung Richard (Executive Director and CFO), among 8 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
